Jiangsu Sihuan Bioengineering Co., Ltd

Symbol: 000518.SZ

SHZ

2.6

CNY

Market price today

  • -40.7351

    P/E Ratio

  • -12.5939

    PEG Ratio

  • 2.68B

    MRK Cap

  • 0.00%

    DIV Yield

Jiangsu Sihuan Bioengineering Co., Ltd (000518-SZ) Stock Price & Analysis

Shares Outstanding

1029.56M

Gross Profit Margin

0.71%

Operating Profit Margin

-0.25%

Net Profit Margin

-0.25%

Return on Assets

-0.09%

Return on Equity

-0.12%

Return on Capital Employed

-0.11%

Company general description and statistics

Sector: Healthcare
Industry: Biotechnology
CEO:Mr. Yu Guo
Full-time employees:250
City:Jiangyin
Address:No. 7 Binjiang East Road
IPO:1993-09-08
CIK:

Jiangsu Sihuan Bioengineering Co., Ltd. engages in the pharmaceutical business in China. It offers Drewson, an anti-tumor biotherapeutic drug for the treatment of renal cancer, malignant melanoma, and cancerous thoracic and peritoneal effusion; and Xinde Lusheng for the treatment of kidney cancer, melanoma, lung cancer, gastric cancer, malignant lymphoma, breast cancer, ovarian tumor, bowel cancer, bladder cancer, head and neck tumor, leukemia and cancerous pleural effusion, etc. The company also provides Xin grain health, a recombinant human granulocyte colony stimulating factor injection; and Tourbo, a recombinant human erythropoietin injection for the treatment of anemia caused by renal insufficiency, including dialysis and non-dialysis patients. Jiangsu Sihuan Bioengineering Co., Ltd. was founded in 1992 and is headquartered in Jiangyin, China.

General Outlook

In simple terms, Jiangsu Sihuan Bioengineering Co., Ltd has 1029.56 M shares that people are buying and selling right now. When we look at how much money they make before expenses, they keep 0.705% as profit. This shows they're good at controlling costs and are financially stable. Their operating profit, which is money made from regular business activities, is -0.250%. This means they run their business efficiently. Lastly, after paying all their bills, they still have a profit of -0.252%. This tells us they're good at keeping money after all costs.

Return on Investments

The company's asset efficiency, represented by a robust -0.091% return, is a testament to Jiangsu Sihuan Bioengineering Co., Ltd's adeptness in optimizing resource deployment. Jiangsu Sihuan Bioengineering Co., Ltd's utilization of its assets to generate profits is strikingly evident through a noteworthy return on equity of -0.119%. Furthermore, the proficiency of Jiangsu Sihuan Bioengineering Co., Ltd in capital utilization is underscored by a remarkable -0.109% return on capital employed.

Stock Prices

Jiangsu Sihuan Bioengineering Co., Ltd's stock prices have been subject to undulating patterns. The peak stock value during this interval surged to $2.65, while its low point bottomed out at $2.57. This variance in figures offers investors a lucid insight into the roller-coaster ride that is Jiangsu Sihuan Bioengineering Co., Ltd's stock market.

Liquidity Ratios

Analyzing 000518.SZ liquidity ratios reveals its financial health of the firm. The current ratio of 439.85% gauges short-term asset coverage for liabilities. The quick ratio (77.07%) assesses immediate liquidity, while the cash ratio (14.34%) indicates cash reserves.

cards.indicatorcards.value
Current Ratio439.85%
Quick Ratio77.07%
Cash Ratio14.34%

Profitability Ratios

000518.SZ profitability indicators offer a lens into its earnings landscape. A pretax profit margin of -26.23% underscores its earnings before tax deductions. The effective tax rate stands at -1.51%, revealing its tax efficiency. The net income per EBT, 96.24%, and the EBT per EBIT, 104.91%, provide insights into its earnings hierarchy. Lastly, with an EBIT per revenue ratio of -25.00%, we grasp its operational profitability.

cards.indicatorcards.value
Pretax Profit Margin-26.23%
Effective Tax Rate-1.51%
Net Income per EBT96.24%
EBT per EBIT104.91%
EBIT per Revenue-25.00%

Operational Efficiency

Operational metrics shed light on its business agility. With an operating cycle of 4.40, it details the span from stock purchase to revenue. The 1 days it takes to settle debts showcases its creditor relations.

cards.indicatorcards.value
Days of Sales Outstanding77
Days of Inventory Outstanding2166
Operating Cycle2278.16
Days of Payables Outstanding264
Cash Conversion Cycle2014
Receivables Turnover3.26
Payables Turnover1.38
Inventory Turnover0.17
Fixed Asset Turnover2.86
Asset Turnover0.36

Cash Flow Ratios

The cash per share value, 0.02, showcases liquidity position. A payout ratio of -0.01 highlights the portion of earnings distributed as dividends. Lastly, the operating cash flow sales ratio, 0.02, offers insight into cash flow relative to sales.

cards.indicatorcards.value
Free Cash Flow per Share-0.01
Cash per Share0.02
Payout Ratio-0.01
Operating Cash Flow Sales Ratio0.02
Free Cash Flow to Operating Cash Flow Ratio-1.53
Cash Flow Coverage Ratio0.08
Short Term Coverage Ratio0.19
Capital Expenditure Coverage Ratio0.40
Dividend Paid and Capex Coverage Ratio0.37

Debt and Leverage Ratios

Diving into debt and leverage metrics unveils the company's financial structure. The debt ratio, at 7.36%, highlights its total liabilities relative to assets. With a debt-equity ratio of 0.10, we discern the balance between debt and equity financing. The long-term debt to capitalization, 5.24%, and total debt to capitalization, 9.12%, ratios shed light on its capital structure. An interest coverage of -66.45 indicates its ability to manage interest expenses.

cards.indicatorcards.value
Debt Ratio7.36%
Debt Equity Ratio0.10
Long Term Debt to Capitalization5.24%
Total Debt to Capitalization9.12%
Interest Coverage-66.45
Cash Flow to Debt Ratio0.08
Company Equity Multiplier1.37

Per Share Data

Speaking about the per share data offers a perceptive view of financial distribution. The revenue per share, 0.23, provides a glimpse into top-line earnings distributed across each share. Net income per share, -0.07, reflects the portion of profit attributed to each share. The book value per share, 0.47, represents the net asset value distributed per share, while the tangible book value per share, 0.47, excludes intangible assets.

cards.indicatorcards.value
Revenue Per Share0.23
Net Income Per Share-0.07
Book Value Per Share0.47
Tangible Book Value Per Share0.47
Shareholders Equity Per Share0.47
Interest Debt Per Share0.05
Capex Per Share-0.01

Growth Ratios

Delving into growth metrics provides a snapshot of financial expansion. The revenue growth rate, -12.86%, indicates top-line expansion, while the gross profit growth, -14.42%, reveals profitability trends. EBIT growth, -96.28%, and operating income growth, -96.28%, offer insights into operational profitability progression. The net income growth, -41.27%, showcases bottom-line expansion, and the EPS growth, -41.12%, measures the growth in earnings per share.

cards.indicatorcards.value
Revenue Growth-12.86%
Gross Profit Growth-14.42%
EBIT Growth-96.28%
Operating Income Growth-96.28%
Net Income Growth-41.27%
EPS Growth-41.12%
EPS Diluted Growth-41.12%
Weighted Average Shares Growth0.01%
Weighted Average Shares Diluted Growth0.01%
Dividends per Share Growth6.79%
Operating Cash Flow Growth-66.51%
Free Cash Flow Growth-81.89%
10-Year Revenue Growth per Share12.74%
5-Year Revenue Growth per Share-40.50%
3-Year Revenue Growth per Share-53.42%
10-Year Operating CF Growth per Share108.57%
5-Year Operating CF Growth per Share-92.78%
3-Year Operating CF Growth per Share-98.37%
10-Year Net Income Growth per Share-6.40%
5-Year Net Income Growth per Share-155.59%
3-Year Net Income Growth per Share-375.73%
10-Year Shareholders Equity Growth per Share-28.67%
5-Year Shareholders Equity Growth per Share-19.63%
3-Year Shareholders Equity Growth per Share-24.84%
10-Year Dividend per Share Growth per Share-16.43%
5-Year Dividend per Share Growth per Share-71.59%
3-Year Dividend per Share Growth per Share41.65%
Receivables Growth-34.34%
Inventory Growth-0.06%
Asset Growth-10.45%
Book Value per Share Growth-13.57%
Debt Growth-1.74%
R&D Expense Growth-29.06%
SGA Expenses Growth-3.29%

Other Metrics

Venturing into other key metrics unveils diverse facets of financial performance. The enterprise value, 3,468,119,998.3, captures the company's total value, considering both debt and equity. Income quality, -0.02, assesses the reliability of reported earnings. The sales, general, and administrative to revenue ratio, 0.12, gauges operational efficiency, while the research and development to revenue, 13.24%, highlights investment in innovation. The ratio of intangibles to total assets, 4.54%, indicates the value of non-physical assets, and capex to operating cash flow, -502.82%, measures reinvestment capability.

cards.indicatorcards.value
Enterprise Value3,468,119,998.3
Income Quality-0.02
Sales General and Administrative to Revenue0.12
Research and Development to Revenue13.24%
Intangibles to Total Assets4.54%
Capex to Operating Cash Flow-502.82%
Capex to Revenue-3.48%
Capex to Depreciation-33.31%
Graham Number0.88
Return on Tangible Assets-11.93%
Graham Net Net0.13
Working Capital391,230,721
Tangible Asset Value482,772,982
Net Current Asset Value361,185,460
Average Receivables102,930,796
Average Payables51,293,373.5
Average Inventory408,646,483
Days Sales Outstanding127
Days Payables Outstanding256
Days of Inventory On Hand2095
ROIC-14.63%
ROE-0.16%

Valuation Ratios

Exploring the valuation ratios offers insights into perceived market value. The price to book value ratio, 5.04, and the price to book ratio, 5.04, reflect the market's valuation relative to the company's book value. The price to sales ratio, 10.35, provides a perspective on valuation in relation to sales. Ratios like price to free cash flows, -398.02, and price to operating cash flows, 604.89, gauge market valuation against cash flow metrics.

cards.indicatorcards.value
Price Book Value Ratio5.04
Price to Book Ratio5.04
Price to Sales Ratio10.35
Price Cash Flow Ratio604.89
Price Earnings to Growth Ratio-12.59
Enterprise Value Multiple-66.93
Price Fair Value5.04
Price to Operating Cash Flow Ratio604.89
Price to Free Cash Flows Ratio-398.02
Price to Tangible Book Ratio7.14
Enterprise Value to Sales14.73
Enterprise Value Over EBITDA-124.93
EV to Operating Cash Flow2128.16
Earnings Yield-2.19%
Free Cash Flow Yield-0.19%
security
Trusted project
“All information displayed on the site is verified. High quality project and financial performance”
Eugene Alexeev
NumFin Founder and investing enthusiast

Frequently Asked Question

How many company shares are outstanding in 2024?

There are stock number shares outstanding of Jiangsu Sihuan Bioengineering Co., Ltd (000518.SZ) on the SHZ in 2024.

What is P/E ratio of enterprise in 2024?

The current P/E ratio of enterprise is -40.735 in 2024.

What is the ticker symbol of Jiangsu Sihuan Bioengineering Co., Ltd stock?

The ticker symbol of Jiangsu Sihuan Bioengineering Co., Ltd stock is 000518.SZ.

What is company IPO date?

IPO date of Jiangsu Sihuan Bioengineering Co., Ltd is 1993-09-08.

What is company current share price?

Current share price is 2.600 CNY.

What is stock market cap today?

The market cap of stock today is 2676856000.000.

What is PEG ratio in 2024?

The current -12.594 is -12.594 in 2024.

What is the number of employees in 2024?

In 2024 the company has 250.